Targeted medical therapy for angina with non-obstructive coronary arteries
A Randomized Controlled Study of Targeted Medical Therapy Versus Placebo for Angina and Non- Obstructive Coronary Arteries: The MVP-ANOCA Study
This study is testing if a new targeted medication can help people with angina and non-obstructive coronary arteries feel better and improve their quality of life.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Stanford University Academic / other |
| Locations | 1 site (Palo Alto, California) |
| Trial ID | NCT06424834 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of targeted medical therapy in improving symptoms and quality of life for patients suffering from angina and non-obstructive coronary arteries. Participants will receive either active medication or a placebo for a duration of four weeks, following a drug titration phase. The study will assess the impact of these treatments through questionnaires measuring quality of life before and after the intervention, after confirming the cause of chest pain through coronary function testing.
Who should consider this trial
Good fit: Ideal candidates include patients with stable angina who have undergone coronary function testing and have been diagnosed with specific conditions related to non-obstructive coronary arteries.
Not a fit: Patients with acute coronary syndrome, significant epicardial coronary artery disease, or contraindications to the study medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option that significantly alleviates symptoms for patients with angina and non-obstructive coronary arteries.
How similar studies have performed: While there have been studies on angina treatments, this specific approach targeting non-obstructive coronary arteries is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients with stable angina referred to the Stanford University Hospital cardiac catheterization laboratory for clinically indicated coronary function testing are eligible for inclusion into the study. Specific inclusion criteria for randomization: * Absence of significant epicardial coronary artery disease on angiography * Fractional flow reserve \> 0.80 And ≥ 1 of the following: * Epicardial coronary spasm on acetylcholine testing * Microvascular spasm on acetylcholine testing * Coronary flow reserve \< 2.5 * Index of microcirculatory resistance ≥ 25 * Myocardial bridge on intravascular ultrasound with dobutamine resting full-cycle ratio ≤ 0.76 Exclusion Criteria: * Acute coronary syndrome less than one week prior to enrolment * Cardiomyopathy * Contraindications to beta-blockers or calcium channel blockers * Baseline systolic blood pressure \< 95 mmHg * Baseline heart rate \< 55 bpm
Where this trial is running
Palo Alto, California
- Stanford Hospital — Palo Alto, California, United States (Recruiting)
Study contacts
- Principal investigator: Jennifer Tremmel, MD — Stanford University
- Study coordinator: Christopher Wong, MBBS, PhD
- Email: ccywong@stanford.edu
- Phone: (650) 725 5909
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.